Proparacaine

DB00807

small molecule approved vet_approved

Deskripsi

Proparacaine is a topical anesthetic drug of the amino ester group. It is found in ophthalmic solutions at a concentration of 0.5% as the hydrochloride salt.

Struktur Molekul 2D

Berat 294.3892
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Plasma

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

1053 Data
Hyaluronidase (ovine) Hyaluronidase (ovine) can cause an increase in the absorption of Proparacaine resulting in an increased serum concentration and potentially a worsening of adverse effects.
Hyaluronidase (human recombinant) Hyaluronidase (human recombinant) can cause an increase in the absorption of Proparacaine resulting in an increased serum concentration and potentially a worsening of adverse effects.
Hyaluronidase Hyaluronidase can cause an increase in the absorption of Proparacaine resulting in an increased serum concentration and potentially a worsening of adverse effects.
Cyclobenzaprine The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Proparacaine.
Metoclopramide The risk or severity of sedation can be increased when Metoclopramide is combined with Proparacaine.
Lasmiditan The risk or severity of adverse effects can be increased when Lasmiditan is combined with Proparacaine.
Ziprasidone The risk or severity of adverse effects can be increased when Proparacaine is combined with Ziprasidone.
Haloperidol The risk or severity of CNS depression can be increased when Haloperidol is combined with Proparacaine.
Fluoxetine Proparacaine may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.
Oliceridine The risk or severity of hypotension, sedation, death, somnolence, and respiratory depression can be increased when Proparacaine is combined with Oliceridine.
Ropeginterferon alfa-2b The risk or severity of neuropsychiatric effects can be increased when Ropeginterferon alfa-2b is combined with Proparacaine.
Daridorexant The risk or severity of CNS depression can be increased when Proparacaine is combined with Daridorexant.
Baclofen Baclofen may increase the central nervous system depressant (CNS depressant) activities of Proparacaine.
Lidocaine The risk or severity of methemoglobinemia can be increased when Lidocaine is combined with Proparacaine.
Ropivacaine The risk or severity of methemoglobinemia can be increased when Ropivacaine is combined with Proparacaine.
Bupivacaine The risk or severity of methemoglobinemia can be increased when Bupivacaine is combined with Proparacaine.
Cinchocaine The risk or severity of methemoglobinemia can be increased when Cinchocaine is combined with Proparacaine.
Dyclonine The risk or severity of methemoglobinemia can be increased when Dyclonine is combined with Proparacaine.
Procaine The risk or severity of methemoglobinemia can be increased when Procaine is combined with Proparacaine.
Prilocaine The risk or severity of methemoglobinemia can be increased when Prilocaine is combined with Proparacaine.
Meloxicam The risk or severity of methemoglobinemia can be increased when Proparacaine is combined with Meloxicam.
Oxybuprocaine The risk or severity of methemoglobinemia can be increased when Proparacaine is combined with Oxybuprocaine.
Cocaine The risk or severity of methemoglobinemia can be increased when Proparacaine is combined with Cocaine.
Mepivacaine The risk or severity of methemoglobinemia can be increased when Proparacaine is combined with Mepivacaine.
Levobupivacaine The risk or severity of methemoglobinemia can be increased when Proparacaine is combined with Levobupivacaine.
Diphenhydramine The risk or severity of methemoglobinemia can be increased when Proparacaine is combined with Diphenhydramine.
Benzocaine The risk or severity of methemoglobinemia can be increased when Proparacaine is combined with Benzocaine.
Chloroprocaine The risk or severity of methemoglobinemia can be increased when Proparacaine is combined with Chloroprocaine.
Phenol The risk or severity of methemoglobinemia can be increased when Proparacaine is combined with Phenol.
Tetrodotoxin The risk or severity of methemoglobinemia can be increased when Proparacaine is combined with Tetrodotoxin.
Benzyl alcohol The risk or severity of methemoglobinemia can be increased when Proparacaine is combined with Benzyl alcohol.
Capsaicin The risk or severity of methemoglobinemia can be increased when Proparacaine is combined with Capsaicin.
Etidocaine The risk or severity of methemoglobinemia can be increased when Proparacaine is combined with Etidocaine.
Articaine The risk or severity of methemoglobinemia can be increased when Proparacaine is combined with Articaine.
Tetracaine The risk or severity of methemoglobinemia can be increased when Proparacaine is combined with Tetracaine.
Propoxycaine The risk or severity of methemoglobinemia can be increased when Proparacaine is combined with Propoxycaine.
Pramocaine The risk or severity of methemoglobinemia can be increased when Proparacaine is combined with Pramocaine.
Butamben The risk or severity of methemoglobinemia can be increased when Proparacaine is combined with Butamben.
Butacaine The risk or severity of methemoglobinemia can be increased when Proparacaine is combined with Butacaine.
Oxetacaine The risk or severity of methemoglobinemia can be increased when Proparacaine is combined with Oxetacaine.
Ethyl chloride The risk or severity of methemoglobinemia can be increased when Proparacaine is combined with Ethyl chloride.
Butanilicaine The risk or severity of methemoglobinemia can be increased when Proparacaine is combined with Butanilicaine.
Metabutethamine The risk or severity of methemoglobinemia can be increased when Proparacaine is combined with Metabutethamine.
Quinisocaine The risk or severity of methemoglobinemia can be increased when Proparacaine is combined with Quinisocaine.
Cetuximab The risk or severity of methemoglobinemia can be increased when Cetuximab is combined with Proparacaine.
Denileukin diftitox The risk or severity of methemoglobinemia can be increased when Denileukin diftitox is combined with Proparacaine.
Leuprolide The risk or severity of methemoglobinemia can be increased when Leuprolide is combined with Proparacaine.
Peginterferon alfa-2a The risk or severity of methemoglobinemia can be increased when Peginterferon alfa-2a is combined with Proparacaine.
Goserelin The risk or severity of methemoglobinemia can be increased when Goserelin is combined with Proparacaine.
Asparaginase Escherichia coli The risk or severity of methemoglobinemia can be increased when Asparaginase Escherichia coli is combined with Proparacaine.
Interferon alfa-2a The risk or severity of methemoglobinemia can be increased when Interferon alfa-2a is combined with Proparacaine.
Aldesleukin The risk or severity of methemoglobinemia can be increased when Aldesleukin is combined with Proparacaine.
Gemtuzumab ozogamicin The risk or severity of methemoglobinemia can be increased when Gemtuzumab ozogamicin is combined with Proparacaine.
Pegaspargase The risk or severity of methemoglobinemia can be increased when Pegaspargase is combined with Proparacaine.
Trastuzumab The risk or severity of methemoglobinemia can be increased when Trastuzumab is combined with Proparacaine.
Rituximab The risk or severity of methemoglobinemia can be increased when Rituximab is combined with Proparacaine.
Tositumomab The risk or severity of methemoglobinemia can be increased when Tositumomab is combined with Proparacaine.
Alemtuzumab The risk or severity of methemoglobinemia can be increased when Alemtuzumab is combined with Proparacaine.
Octreotide The risk or severity of methemoglobinemia can be increased when Octreotide is combined with Proparacaine.
Interferon alfa-2b The risk or severity of methemoglobinemia can be increased when Interferon alfa-2b is combined with Proparacaine.
Bevacizumab The risk or severity of methemoglobinemia can be increased when Bevacizumab is combined with Proparacaine.
Masoprocol The risk or severity of methemoglobinemia can be increased when Masoprocol is combined with Proparacaine.
Bortezomib The risk or severity of methemoglobinemia can be increased when Bortezomib is combined with Proparacaine.
Pipobroman The risk or severity of methemoglobinemia can be increased when Pipobroman is combined with Proparacaine.
Cladribine The risk or severity of methemoglobinemia can be increased when Cladribine is combined with Proparacaine.
Cabergoline The risk or severity of methemoglobinemia can be increased when Cabergoline is combined with Proparacaine.
Anagrelide The risk or severity of methemoglobinemia can be increased when Anagrelide is combined with Proparacaine.
Carmustine The risk or severity of methemoglobinemia can be increased when Carmustine is combined with Proparacaine.
Chlorotrianisene The risk or severity of methemoglobinemia can be increased when Chlorotrianisene is combined with Proparacaine.
Amsacrine The risk or severity of methemoglobinemia can be increased when Amsacrine is combined with Proparacaine.
Pamidronic acid The risk or severity of methemoglobinemia can be increased when Pamidronic acid is combined with Proparacaine.
Bleomycin The risk or severity of methemoglobinemia can be increased when Bleomycin is combined with Proparacaine.
Chlorambucil The risk or severity of methemoglobinemia can be increased when Chlorambucil is combined with Proparacaine.
Raltitrexed The risk or severity of methemoglobinemia can be increased when Raltitrexed is combined with Proparacaine.
Mitomycin The risk or severity of methemoglobinemia can be increased when Mitomycin is combined with Proparacaine.
Bexarotene The risk or severity of methemoglobinemia can be increased when Bexarotene is combined with Proparacaine.
Vindesine The risk or severity of methemoglobinemia can be increased when Vindesine is combined with Proparacaine.
Valproic acid The risk or severity of methemoglobinemia can be increased when Valproic acid is combined with Proparacaine.
Gefitinib The risk or severity of methemoglobinemia can be increased when Gefitinib is combined with Proparacaine.
Floxuridine The risk or severity of methemoglobinemia can be increased when Floxuridine is combined with Proparacaine.
Megestrol acetate The risk or severity of methemoglobinemia can be increased when Megestrol acetate is combined with Proparacaine.
Tioguanine The risk or severity of methemoglobinemia can be increased when Tioguanine is combined with Proparacaine.
Aminoglutethimide The risk or severity of methemoglobinemia can be increased when Aminoglutethimide is combined with Proparacaine.
Vinorelbine The risk or severity of methemoglobinemia can be increased when Vinorelbine is combined with Proparacaine.
Valrubicin The risk or severity of methemoglobinemia can be increased when Valrubicin is combined with Proparacaine.
Sorafenib The risk or severity of methemoglobinemia can be increased when Sorafenib is combined with Proparacaine.
Streptozocin The risk or severity of methemoglobinemia can be increased when Streptozocin is combined with Proparacaine.
Trifluridine The risk or severity of methemoglobinemia can be increased when Trifluridine is combined with Proparacaine.
Gemcitabine The risk or severity of methemoglobinemia can be increased when Gemcitabine is combined with Proparacaine.
Teniposide The risk or severity of methemoglobinemia can be increased when Teniposide is combined with Proparacaine.
Epirubicin The risk or severity of methemoglobinemia can be increased when Epirubicin is combined with Proparacaine.
Lenalidomide The risk or severity of methemoglobinemia can be increased when Lenalidomide is combined with Proparacaine.
Altretamine The risk or severity of methemoglobinemia can be increased when Altretamine is combined with Proparacaine.
Flutamide The risk or severity of methemoglobinemia can be increased when Flutamide is combined with Proparacaine.
Cisplatin The risk or severity of methemoglobinemia can be increased when Cisplatin is combined with Proparacaine.
Alitretinoin The risk or severity of methemoglobinemia can be increased when Alitretinoin is combined with Proparacaine.
Oxaliplatin The risk or severity of methemoglobinemia can be increased when Oxaliplatin is combined with Proparacaine.
Erlotinib The risk or severity of methemoglobinemia can be increased when Erlotinib is combined with Proparacaine.
Cyclophosphamide The risk or severity of methemoglobinemia can be increased when Cyclophosphamide is combined with Proparacaine.
Toremifene The risk or severity of methemoglobinemia can be increased when Toremifene is combined with Proparacaine.

Target Protein

Sodium channel protein type 10 subunit alpha SCN10A

Referensi & Sumber

Belum ada data referensi/link/attachment untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field referensi.

Contoh Produk & Brand

Produk: 35 • International brands: 5
Produk
  • Alcaine
    Solution / drops • 5 mg/1mL • Ophthalmic • US • Generic • Approved
  • Alcaine
    Solution / drops • 5 mg/1mL • Ophthalmic • US • Generic • Approved
  • Alcaine
    Solution / drops • 0.5 % w/v • Ophthalmic • Canada • Approved
  • Flucaine
    Solution / drops • - • Ophthalmic • US
  • Fluorescein Sodium and Proparacaine Hydrochloride
    Solution / drops • - • Ophthalmic • US
  • Mydriatic-4
    Solution / drops • - • Ophthalmic • US
  • Odan-fluoracaine
    Solution • - • Ophthalmic • Canada • Generic • Approved
  • Odan-proparacaine
    Solution • .5 % • Ophthalmic • Canada • Generic • Approved
Menampilkan 8 dari 35 produk.
International Brands
  • Ak-Taine
  • Diocaine
  • Ocu-Caine
  • Ophthaine
  • Spectro-Caine

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul